Kira Zaslavskaya: It is our responsibility to ensure the interaction of business with research institutes

Solutions that will help preserve the innovativeness of the domestic pharmaceutical industry in modern realities were announced by Kira Zaslavskaya, Director of New Products at Promomed Group in her speech at the Pharma-2022 conference: launching a strategy for the development of the pharmaceutical industry until 2030.

"As a full-cycle manufacturer with our own R&D resources, we consider it socially responsible and important to interact with research institutes. In particular, Promomed has become an industrial partner for a number of fundamental research projects at Sirius University, Mordovian State University, the Endocrinology Research Center, and others. We believe that this practice should be continued.

Interdisciplinary conferences are now becoming a particularly important format that allows bringing together not only doctors and representatives of research institutes, but also participants in the pharmaceutical industry, which in turn will accelerate innovation, expand dialogue, and create a unified information space.

The implementation of the idea of forming a common R&D inventory platform and creating a common drug search system, announced in the Pharma 2030 program, will not only streamline the search for new molecules, but will also certainly serve as cooperation between pharmaceutical manufacturers," Kira Zaslavskaya said, among others.